TET2 and chronic myelogenous leukemia, BCR-ABL1 positive: For example, while the mutation rate of TET2 (whose mutation was known to be more associated with advanced-phase CML than chronic-phase CML; refs. 56, 57) was 3.7% in CML in THAMP, it was 26.3% in CML in AACR GENIE 10.0-public (Fig. 1F).